These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36503478)

  • 1. Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
    Shang K; Huang H; Xu Y; Liu Y; Lu Z; Chen L
    BMC Cancer; 2022 Dec; 22(1):1295. PubMed ID: 36503478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
    Xu Y; Ji H; Zhang Y; Xiong L; Han B; Zhong H; Xu J; Zhong R
    Oncologist; 2024 Jul; 29(7):e932-e940. PubMed ID: 38529688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update.
    Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J
    Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
    Chul Cho B; Han JY; Hyeong Lee K; Lee YG; Kim DW; Joo Min Y; Kim SW; Kyung Cho E; Kim JH; Lee GW; Sook Lee S; Lee N; Young Wang J; Park H; Ahn MJ
    Lung Cancer; 2024 Apr; 190():107509. PubMed ID: 38432025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer.
    Xiang H; Danna D; Xuefei C; Zhao J; Jin G
    Anticancer Drugs; 2024 Jun; 35(5):433-439. PubMed ID: 38410975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma.
    Vokes NI; Chambers E; Nguyen T; Coolidge A; Lydon CA; Le X; Sholl L; Heymach JV; Nishino M; Van Allen EM; Jänne PA
    J Thorac Oncol; 2022 Jun; 17(6):779-792. PubMed ID: 35331964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant
    Canale M; Petracci E; Delmonte A; Bronte G; Chiadini E; Ludovini V; Dubini A; Papi M; Baglivo S; De Luigi N; Verlicchi A; Chiari R; Landi L; Metro G; Burgio MA; Crinò L; Ulivi P
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32272775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
    Blasi M; Kuon J; Lüders H; Misch D; Kauffmann-Guerrero D; Hilbrandt M; Kazdal D; Falkenstern-Ge RF; Hackanson B; Dintner S; Faehling M; Kirchner M; Volckmar AL; Kopp HG; Allgäuer M; Grohé C; Tufman A; Reck M; Frost N; Stenzinger A; Thomas M; Christopoulos P
    Eur J Cancer; 2024 Mar; 199():113556. PubMed ID: 38271745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
    Shao Y; Zhang J; Feng Z; Wu W; Zhao X; Zhu M; Xiao Y; Pang J; Zhu J; Qu H; Yuan M; Xia G; Liu M; Li H
    Cancer Sci; 2024 Jun; ():. PubMed ID: 38932450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer.
    Zhang X; Zhang M; Du X; Zhang G; Niu Y; Wei C; Guo L; Shi C; Liu H; Wang H
    Front Pharmacol; 2024; 15():1331138. PubMed ID: 38655174
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations.
    Shimoda Y; Yoshida T; Miyakoshi J; Torasawa M; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2023 Aug; 72(8):2613-2621. PubMed ID: 37062033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.
    Bai B; An X; Qu Q; Liu X; Liu Y; Wei L
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38872053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Chen CH; Lee HH; Chuang HY; Hung JY; Huang MY; Chong IW
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.
    Nishino M; Lu J; Hino T; Vokes NI; Jänne PA; Hatabu H; Johnson BE
    J Thorac Imaging; 2023 Mar; 38(2):82-87. PubMed ID: 34524205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Data on Prognostic Factors for Overall Survival in EGFR-Mutant Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Yu X; Fan Y
    J Cancer; 2019; 10(15):3486-3493. PubMed ID: 31293653
    [No Abstract]   [Full Text] [Related]  

  • 18. Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.
    Zhang Z; Xue J; Yang Y; Fang W; Huang Y; Zhao S; Luo F; Cao J; Zeng K; Ma W; Zhan J; Lu F; Zhang L; Zhao H
    MedComm (2020); 2024 Jun; 5(6):e586. PubMed ID: 38832214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma.
    Qiao X; Zhang Y; Wang J; Nong J; Li X; Yang X; Lv J; Zhang H; Qin N; Zhang Q; Yue W; Zhang S
    Thorac Cancer; 2015 Nov; 6(6):678-86. PubMed ID: 26557904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases.
    Lee CC; Hsu SPC; Lin CJ; Wu HM; Chen YW; Luo YH; Chiang CL; Hu YS; Chung WY; Shiau CY; Guo WY; Hung-Chi Pan D; Yang HC
    J Neurosurg; 2019 Jun; 133(2):313-320. PubMed ID: 31226692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.